Advertisement
UK markets close in 8 hours 13 minutes
  • FTSE 100

    7,950.89
    +18.91 (+0.24%)
     
  • FTSE 250

    19,802.66
    -8.00 (-0.04%)
     
  • AIM

    742.11
    0.00 (0.00%)
     
  • GBP/EUR

    1.1683
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2609
    -0.0029 (-0.23%)
     
  • Bitcoin GBP

    55,768.73
    +273.26 (+0.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.86
    +0.51 (+0.63%)
     
  • GOLD FUTURES

    2,212.00
    -0.70 (-0.03%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,558.25
    +165.41 (+1.01%)
     
  • DAX

    18,485.62
    +8.53 (+0.05%)
     
  • CAC 40

    8,216.60
    +11.79 (+0.14%)
     

Reckitt Benckiser to develop XenoPort alcohol abuse drug

LONDON, May 15 (Reuters) - Reckitt Benckiser Group's pharmaceuticals unit will develop and sell XenoPort Inc (NasdaqGS: XNPT - news) 's drug to treat alcohol use disorders, the companies said on Thursday.

Under the terms of the exclusive global licensing deal, XenoPort is entitled to $20 million up front, followed by another $5 million upon the transfer of certain technology and materials and aggregate payments of up to $70 million upon Reckitt's achievement of development and regulatory milestones, and $50 million for commercial milestones.

(Reporting by Martinne Geller; Editing by Erica Billingham)